Reversal of Hyperglycemia and Suppression of Type 1 Diabetes in the NOD Mouse with Apoptotic DNA Immunotherapy™ (ADi™), ADi-100
Open Access
- 3 March 2020
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 8 (3), 53
- https://doi.org/10.3390/biomedicines8030053
Abstract
The antigen-specific apoptotic DNA immunotherapeutic, ADi-100, is designed to suppress type 1 diabetes and consists of two DNA plasmids encoding genetic sequences of the apoptosis-inducing molecule, BAX, and the secreted form of the autoantigen, glutamic acid decarboxylase 65, that is CpG hyper-methylated to avoid inflammatory signaling (msGAD55). Upon a four-day treatment with ADi-100 of young female non-obese diabetic (NOD) mice, the frequency of various tolerogenic dendritic cell populations increased in draining lymph nodes; these cells lost the capacity to stimulate glutamic acid decarboxylase (GAD)-specific CD4+ T lymphocytes and were associated with the previously demonstrated enhancement of GAD-specific regulatory T cells. The efficacy of two ADi-100 formulations containing different proportions of BAX and msGAD55, 1:4 (10/40 µg) and 1:2 (17/33 µg), was evaluated in mildly hyperglycemic pre-diabetic NOD female mice. Both formulations suppressed the incidence of diabetes by 80% in an antigen-specific manner, while all untreated mice developed diabetes. However, treatment of pre-diabetic mice with significantly higher hyperglycemia, denoting progressive disease, showed that ADi-100 1:2 strongly suppressed diabetes incidence by 80% whereas the ADi-100 1:4 was less effective (50%). As an antigen-specific monotherapy, ADi-100 is highly efficacious in reversing elevated hyperglycemia to prevent diabetes, in which increasing apoptosis-inducing BAX content is a promising immune tolerance feature.Keywords
This publication has 41 references indexed in Scilit:
- Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?Diabetologia, 2017
- Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune diseaseProceedings of the National Academy of Sciences of the United States of America, 2017
- Obstacles and opportunities for targeting the effector T cell response in type 1 diabetesJournal of Autoimmunity, 2016
- Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigensScientific Reports, 2015
- Exploiting Apoptosis for Therapeutic Tolerance InductionThe Journal of Immunology, 2013
- Diminished Adenosine A1 Receptor Expression in Pancreatic α-Cells May Contribute to the Pathology of Type 1 DiabetesDiabetes, 2013
- DNA vaccines for transplantationExpert Opinion on Biological Therapy, 2010
- A therapeutic DNA vaccination strategy for autoimmunity and transplantationVaccine, 2010
- Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitroVaccine, 2006
- Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in miceVaccine, 2004